Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ULK1 | O75385 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14424640 | 1.00 | NPY5R (0.42) | NPY5RMAPTGRIA2KMT2AMEN1 | |
| SCHEMBL10114888 | 1.00 | NPY5R (0.42) | NPY5RMAPTGRIA2KMT2AMEN1 | |
| SCHEMBL10114716 | 0.84 | MAPT (0.55) | NPY5RMAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL10116039 | 0.83 | RBP4 (0.41) | GRIA2KMT2AMEN1 | |
| SCHEMBL10133536 | 0.83 | CCR8 (0.37) | NPY5RGRIA2KMT2AMEN1LMNA | |
| SCHEMBL10114847 | 0.83 | NPY5R (0.49) | NPY5RKMT2AMEN1RAB9ATSHR | |
| SCHEMBL14424629 | 0.83 | NPY5R (0.49) | NPY5RKMT2AMEN1RAB9ATSHR | |
| SCHEMBL10114890 | 0.82 | KMT2A (0.46) | NPY5RMAPTGRIA2KMT2AMEN1 | |
| SCHEMBL14424635 | 0.82 | KMT2A (0.46) | NPY5RMAPTGRIA2KMT2AMEN1 | |
| SCHEMBL10114955 | 0.81 | NPY5R (0.45) | NPY5RMAPTGRIA2LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | NPY5R 1/4885MAPT 3602/4885GRIA2 347/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | NPY5R 1/4885MAPT 3367/4885GRIA2 334/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | NPY5R 1/4885MAPT 3683/4885GRIA2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.